About us
Our vision
At Sortina, the overall goal is to create life-saving, world-class small molecule therapeutics targeting sortilin. By using the sortilin approach we aim to develop molecules characterized by superior efficacy and safety, providing novel tools for treatment of cancer, neurodegenerative diseases, and beyond.
Our strategy
Sortina’s strategy is to drive the development of an oncology drug candidate in-house, with primary focus on Glioblastoma Multiforme, until clinical proof of concept has been reached and partnering agreement is established.
In parallel with the oncology program, our platform also advances the development of distinct small molecule structures, offering partnership opportunities for neurodegenerative diseases, and beyond.
Sortina Pharma´s Platform Pipeline
Our innovative approach leverages small molecules targeting sortilin (SORT-molecules), addressing the challenging Glioblastoma Multiforme cancer and paving the way for additional sortilin-driven cancers such as Breast Cancer, Pancreatic Cancer and Melanoma.
In parallel with the oncology program, the Sortina development platform has generated great advancement of selected small molecule structures with superior properties for partnering opportunities in the area of neurodegenerative diseases and beyond.
